RenovoRx releases investor presentation outlining RenovoCath commercialization, TAMP oncology platform and Phase III TIGeR-PaC trial in pancreatic cancer

RenovoRx, Inc.

RenovoRx, Inc.

RNXT

0.00
  • RenovoRx highlighted a push to expand adoption of its FDA-cleared RenovoCath drug-delivery device, with 16 commercial centers as of May 15, 2026.
  • Projected peak annual U.S. revenue opportunity of about $400 million for RenovoCath as a standalone device, based on internal estimates.
  • Phase III TIGeR-PaC trial in locally advanced pancreatic cancer targets enrollment completion by end of June 2026; final data expected mid-to-late 2027.
  • Trial status update showed 106 patients randomized as of May 14, 2026; 74 deaths recorded toward the 86 events required for final analysis.
  • Commercial ramp cited $1.1 million RenovoCath revenue in 2025; Q1 2026 revenue of $563,000; Q2 2026 expected to exceed Q1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.